This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Pacira BioSciences Class Action Deadline
Business class action

Pacira BioSciences Class Action Deadline

Analysis based on 15 articles · First reported Feb 03, 2025 · Last updated Feb 18, 2025

Sentiment
-20
Attention
3
Articles
15
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Pacira BioSciences, Inc. could negatively impact its stock price and reputation due to allegations of misleading statements regarding its Exparel patent protections. Investors who purchased Pacira BioSciences, Inc. securities during the Class Period may be entitled to compensation, potentially affecting the company's financial outlook.

Pharmaceuticals Legal Services
Event Summary

Rosen Law Firm is reminding investors of the March 14, 2025, lead plaintiff deadline for a class action lawsuit against Pacira BioSciences, Inc. The lawsuit alleges that Pacira BioSciences, Inc. made false and misleading statements between August 2, 2023, and August 8, 2024, concerning the patent protections for its drug Exparel. According to the lawsuit, Pacira BioSciences, Inc. created a false impression of strong patent protection for Exparel, which was crucial for its growth and revenue. However, the '495 patent was not as protective as publicly touted, evidenced by a June 6, 2023, ruling by the United States — United States District Court for the District of New Jersey in favor of eVenus regarding claims construction. Despite this, Pacira BioSciences, Inc. allegedly continued to affirm its belief in the patent's protection, leading to investor damages when the true details emerged.

Key Actions
90 Pacira BioSciences made false statements
80 Rosen Law Firm reminds purchasers
Entities Involved
stock
Pacira BioSciences
Pacira BioSciences is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its patent protections for Exparel, leading to investor damages.
Importance 100.0 Sentiment -40.0
govactor
United States — United States District Court for the District of New Jersey
The United States — United States District Court for the District of New Jersey issued a ruling in eVenus's favor regarding claims construction, which is cited as evidence that Pacira BioSciences' patent protections for Exparel were fragile.
Importance 50.0 Sentiment 0.0
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is listed as a contact for investors interested in joining the class action lawsuit against Pacira BioSciences, Inc.
Importance 40.0 Sentiment 10.0
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is mentioned for his firm's track record in securities class actions and as a contact for the Pacira BioSciences, Inc. lawsuit.
Importance 40.0 Sentiment 10.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
Relationships
United States — United States District Court for the District of New Jersey related ↔ Philip Kim
United States — United States District Court for the District of New Jersey related ↔ Rosen Law Firm
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
Philip Kim attorney ↔ Rosen Law Firm Philip Kim is an attorney at Rosen Law Firm, where he acts as a key contact and represents investors in various securiti
Lawrence Rosen founding partner ↔ Rosen Law Firm Lawrence Rosen is a founding partner of the Rosen Law Firm, a prominent legal practice specializing in securities class
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.